Lucem Health vs Oatmeal Health (2026)
Both run early detection as a programme rather than as an algorithm, which is the right instinct, and they scope it differently. Lucem covers several conditions under one operating model, from lung and colorectal cancer through liver disease and arrhythmias, founded with Mayo Clinic. Oatmeal does lung cancer screening in federally qualified health centres, which is the hardest and most underserved version of that job: the eligible population is large, capacity is thin and the failure is almost never identification but navigation and follow through. For a safety net organisation, Oatmeal is built for the setting rather than adapted to it. Both should be asked to report screening and follow through by race and insurance status, because a programme that lifts the average while widening the gap has not helped the people it was sold to reach.
- Early detection runs as a programme across several conditions rather than one, so a health system builds the outreach and confirmatory workflow once and reuses it.
- The Mayo Clinic founding relationship is a real institutional grounding rather than an advisory listing.
- For an organisation wanting detection across a portfolio, a programme operator is a different and more complete purchase than an algorithm.
- It targets lung cancer screening specifically in federally qualified health centres, which is where screening uptake is lowest and the eligible population is largest relative to capacity.
- Screening programmes in that setting fail on navigation and follow through rather than on identification, and the product is built around that reality.
- Focusing on one cancer in one setting makes the economics legible in a way a multi condition programme is not.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Lucem Health and Oatmeal Health are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Lucem Health | Oatmeal Health |
|---|---|---|
| Primary category | Clinical Decision Support | Value Based Care Intelligence |
| Founded | Not recorded | 2022 |
| Headquarters | Davidson, North Carolina, United States | San Jose, California, United States |
| Website | lucemhealth.com | oatmealhealth.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index records no top capability grade for Lucem Health on any axis it scores. Set against Oatmeal Health, Lucem Health grades higher on several axes, including Autonomy and Oversight Model, Model Supply Chain Disclosure and Clinical and Operational Evidence. Its thinnest published disclosure sits on several axes, including AI Centrality, HIPAA and BAA Posture and Security Certifications and Trust Center. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index records no top capability grade for Oatmeal Health on any axis it scores. Set against Lucem Health, Oatmeal Health grades higher on AI Centrality, AI Governance and Bias Disclosure and AI Liability and Recourse. Its thinnest published disclosure sits on several axes, including Model Supply Chain Disclosure, Clinical and Operational Evidence and HIPAA and BAA Posture. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Lucem Health or Oatmeal Health?
On the axes where the AI Health Index separates them, Lucem Health grades higher on several axes, including Autonomy and Oversight Model, Model Supply Chain Disclosure and Clinical and Operational Evidence, and Oatmeal Health grades higher on AI Centrality, AI Governance and Bias Disclosure and AI Liability and Recourse. Lucem Health leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Lucem Health and Oatmeal Health differ most?
The widest separation the AI Health Index records between Lucem Health and Oatmeal Health is on AI Centrality, where Lucem Health grades D and Oatmeal Health grades B. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Lucem Health and Oatmeal Health grade the same?
The AI Health Index grades Lucem Health and Oatmeal Health the same on several axes, including Model and Technology Transparency, AI Safety and PHI Stewardship and HIPAA and BAA Posture. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Lucem Health and Oatmeal Health not disclosed?
At the last review, at least one of Lucem Health and Oatmeal Health published thin or absent detail on several axes, including AI Centrality, Model Supply Chain Disclosure and Clinical and Operational Evidence. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Lucem's models are developed by partner companies, so accuracy, drift and subgroup performance questions route to a third party the health system does not contract with, which is the concentration risk on that record. Neither vendor publishes a retention position, secondary use policy or subgroup performance analysis.
Lung cancer screening in particular carries a well documented equity gap in both eligibility criteria and uptake, so any programme should be asked to report screening rates and follow through by race and insurance status rather than in aggregate, since an intervention that lifts the average while widening the gap is not a success.